DUX4 expression in FSHD muscle cells: How could such a rare protein cause a myopathy? by Tassin, Alexandra et al.
Himmelfarb Health Sciences Library, The George Washington University
Health Sciences Research Commons
Genomics and Precision Medicine Faculty
Publications Genomics and Precision Medicine
1-2013
DUX4 expression in FSHD muscle cells: How
could such a rare protein cause a myopathy?
Alexandra Tassin
University of Mons, Mons, Belgium
Dalila Laoudj-Chenivesse
University of Mons, Mons, Belgium
Celine Vanderplanck
University of Mons, Mons, Belgium
Marietta Barro
INSERM, Montpelier, France
Sebastien Charron
University of Mons, Mons, Belgium
See next page for additional authors
Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_intsysbio_facpubs
Part of the Systems Biology Commons
This Journal Article is brought to you for free and open access by the Genomics and Precision Medicine at Health Sciences Research Commons. It has
been accepted for inclusion in Genomics and Precision Medicine Faculty Publications by an authorized administrator of Health Sciences Research
Commons. For more information, please contact hsrc@gwu.edu.
Recommended Citation
Tassin A, Laoudj-Chenivesse D, Vanderplanck C, Barro M, Charron S, Ansseau E, Chen YW, Mercier J, Coppée F, Belayew A. (2013).
DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy? Journal of Cellular and Molecular
Medicine, 17(1), 76-89.
Authors
Alexandra Tassin, Dalila Laoudj-Chenivesse, Celine Vanderplanck, Marietta Barro, Sebastien Charron,
Eugenie Ansseau, Yi-Wen Chen, Jacques Mercier, Frederique Coppee, and Alexandra Belayew
This journal article is available at Health Sciences Research Commons: http://hsrc.himmelfarb.gwu.edu/smhs_intsysbio_facpubs/51
DUX4 expression in FSHD muscle cells:
how could such a rare protein cause a myopathy?
Alexandra Tassin a, Dalila Laoudj-Chenivesse b, §, Ce´line Vanderplanck a, §, Marietta Barro b,
Se´bastien Charron a, Euge´nie Ansseau a, Yi-Wen Chen c, Jacques Mercier b, Fre´de´rique Coppe´e a, #,
Alexandra Belayew a, #, *
a Laboratory of Molecular Biology, Research Institute for Health Sciences and Technology,
University of Mons, Mons, Belgium
b INSERM U1046 Physiologie et Me´decine expe´rimentale Cœur et Muscle, CHU A. de Villeneuve, Montpellier, France
c Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
Received: May 3, 2012; Accepted: September 15, 2012
Abstract
Facioscapulohumeral muscular dystrophy (FSHD) is one of the most frequent hereditary muscle disorders. It is linked to contractions of the
D4Z4 repeat array in 4q35. We have characterized the double homeobox 4 (DUX4) gene in D4Z4 and its mRNA transcribed from the distal D4Z4
unit to a polyadenylation signal in the flanking pLAM region. It encodes a transcription factor expressed in FSHD but not healthy muscle cells
which initiates a gene deregulation cascade causing differentiation defects, muscle atrophy and oxidative stress. PITX1 was the first identified
DUX4 target and encodes a transcription factor involved in muscle atrophy. DUX4 was found expressed in only 1/1000 FSHD myoblasts. We
have now shown it was induced upon differentiation and detected in about 1/200 myotube nuclei. The DUX4 and PITX1 proteins presented
staining gradients in consecutive myonuclei which suggested a diffusion as known for other muscle nuclear proteins. Both protein half-lifes
were regulated by the ubiquitin-proteasome pathway. In addition, we could immunodetect the DUX4 protein in FSHD muscle extracts. As a
model, we propose the DUX4 gene is stochastically activated in a small number of FSHD myonuclei. The resulting mRNAs are translated in
the cytoplasm around an activated nucleus and the DUX4 proteins diffuse to adjacent nuclei where they activate target genes such as PITX1.
The PITX1 protein can further diffuse to additional myonuclei and expand the transcriptional deregulation cascade initiated by DUX4. Together
the diffusion and the deregulation cascade would explain how a rare protein could cause the muscle defects observed in FSHD.
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Introduction
Facioscapulohumeral muscular dystrophy (FSHD1A: OMIM #158900)
is one of the most common hereditary muscle disorders, affecting
seven individuals in 100,000 (http://www.orpha.net), and is associ-
ated with contractions of the D4Z4 repeat array in the 4q35 subtelo-
meric region [1–3]. In non-affected individuals, this array comprises
11–100 tandem copies of the 3.3-kb D4Z4 element, whereas in
patients with FSHD, only 1–10 D4Z4 copies are left [1, 3], and at least
one D4Z4 copy is necessary to develop the disorder [4]. A similar
DNA hypomethylation associated with an open chromatin structure is
observed both on contracted D4Z4 arrays in FSHD1A and on normal-
size arrays in FSHD1B (OMIM #158901) [5–7]. Our group has identi-
fied the double homeobox 4 (DUX4) gene within each D4Z4 unit [8]
but detection of its mRNA proved very difficult because of its very low
abundance and high GC content (discussed in supporting information
of [9]). We could identify stable DUX4 mRNAs in FSHD muscle cells
and show that they were transcribed from the most distal D4Z4 unit
of the repeat array and extended to a polyadenylation signal in the
flanking pLAM region [9]. Those findings were confirmed by other
groups which further demonstrated this polyadenylation site was
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required for DUX4 mRNA stabilization and to develop FSHD from a
contracted allele [10]. The full-length mRNA (DUX4-fl) transcribed
from this distal D4Z4 unit contains the entire DUX4 open-reading
frame (ORF) [9, 11, 12]. In addition, a shorter transcript (DUX4-s)
that might express a protein limited to its double homeodomain was
described [11]. The DUX4-fl mRNA was detected in most FSHD
muscle cells and biopsies, whereas the DUX4-s mRNA was detected
both in healthy control and some FSHD samples [11]. The DUX4-fl
mRNA was also detected in FSHD1B muscle cells [11]. In addition,
we have characterized a DUX4 homologue mapped 42 kb centromeric
of the D4Z4 repeat array and named DUX4c. The encoded protein is
expressed in healthy muscle cells and induced in FSHD [13]. Because
it activates myoblast proliferation and inhibits their differentiation,
DUX4c might be involved in muscle regeneration, and changes in its
expression could contribute to the FSHD pathology [13–15]. In aggre-
gate, our discovery of the functional DUX4 and DUX4c genes in
repeated DNA elements has contributed to the obsolescence of the
‘junk DNA’ concept [16].
Detection of the DUX4 protein proved a technical challenge
because of its particularly low abundance. Our initial detection in pri-
mary FSHD but not control myoblast cultures [9] was confirmed by
Snider et al. who found it was in fact expressed at a relatively abun-
dant level in very few nuclei (1/1000 myoblasts) [11]. DUX4 overex-
pression in cell cultures led to cell death [17]. Intriguingly, myotubes,
but not myoblasts, were somehow protected against DUX4-induced
cell death [18–20]. The DUX4 protein is a transcription factor that tar-
gets a large set of genes, some of which encode other transcription
factors that in turn target additional genes [9, 18, 19, 21]. Indeed,
DUX4 directly activates the PITX1 (Paired-like homeodomain transcrip-
tion factor 1) gene which is specifically induced 10- to 15-fold in FSHD
muscles as compared with 11 other neuromuscular disorders [9]. The
PITX1 protein itself is a homeodomain transcription factor involved in
hindlimb identity specification during embryogenesis, and can induce
adult muscle atrophy [22]. A large number of genes were identified in
the deregulation cascade caused by DUX4 overexpression either in
mouse C2C12 cells [18] or human primary myoblasts [21]. DUX4
expression in myoblast cultures recapitulated key features of the FSHD
molecular phenotype, i.e. repression of MyoD and its target genes
leading to diminished myogenic differentiation, repression of glutathi-
one oxydo-reduction pathway components resulting in increased sen-
sitivity to oxidative stress, muscle atrophy and activation of germline-
specific genes [18, 19, 21]. We have recently demonstrated the DUX4
causal role in the atrophy process by gain and loss of function experi-
ments in primary human myoblasts followed by differentiation to myo-
tubes. DUX4 overexpression induced hypomorphic myotube formation
associated with the induction of E3 ubiquitin ligases (MURF1 and Atro-
gin1) typical of muscle atrophy, whereas RNA interference or antisense
oligonucleotides targeting the DUX4 mRNA reversed this phenotype
[16]. In addition, DUX4 overexpression in mouse muscles in vivo
caused a TP53-dependent myopathy requiring the DUX4 DNA binding
domain [23]. In aggregate, these studies confirmed the major role
played by DUX4 in the pathological mechanism of FSHD through the
initiation of a large transcription deregulation cascade (reviewed in
[20]). The question that still remained unclear was how such a scarce
protein could lead to the muscle pathology in FSHD.
In the present study, we focused on DUX4 protein expression and
degradation in FSHD myotubes. Barro et al. have established a panel
of primary CD56+ myoblasts derived from patients with FSHD and
matched healthy individuals (controls) [24]. These FSHD myoblasts
fused and differentiated into myotubes with morphological abnormali-
ties: they were either thin ‘atrophic’ myotubes or disorganized ones
with clusters of non-aligned nuclei. Both phenotypes were found in
different proportions in each myotube culture derived from a patient
with FSHD. A myotube is a multinucleated syncitium in which nuclei
share a large cytoplasm. Both muscle-specific or housekeeping genes
are transcribed in stochastic pulses that occur independently in indi-
vidual myonuclei [25]. The mRNAs expressed from a given myonu-
cleus are translated in its adjacent cytoplasmic domain, and if the
synthesized proteins carry a nuclear localization signal (NLS), they
are imported into this active nucleus. As initially shown with a beta-
galactosidase protein fused to a NLS, these proteins can also be
imported at a reduced level into nuclei on either side of the source of
expression [26]. This diffusion phenomenon was confirmed by sev-
eral research groups [25, 27, 28], but was never described in patho-
logical myotubes. In this study we have investigated DUX4 and PITX1
expression in myotubes from affected and non-affected muscles of
patients with different age or gender. Our results suggest that as
described for other muscle transcription factors, the DUX4 protein
appears in a single nucleus where the gene is likely stochastically
activated and diffuses to adjacent myonuclei. We propose that this
DUX4 expression pulse initiates a transcriptional amplification cas-
cade [19] that progressively extends in consecutive myonuclei to the
whole myotube causing the FSHD pathological phenotype.
Materials and methods
Muscle biopsies and ethics statement
Primary human myoblasts, muscle biopsies and surgical muscle surplus
during scapular fixation were obtained according to procedures approved
by the current ethical and legislative rules of France or Belgium and written
informed consent was obtained from all participants, as directed by the eth-
ical committee of CHU de Villeneuve (Montpellier, France) [24]. In addition,
the uses of this material have been approved by the ethics committee of
the University of Mons (ref #A901). We used clinical and histopathology
criteria as described [24] to assess whether the biopsied muscle was
affected and to evaluate the severity.
Cell Culture
C2C12 (mouse myoblasts) and TE671 (human rhabdomyosarcoma) cells
were grown in DMEM high glucose (4.5 g/l) with L-glutamine and sodium
pyruvate (PAA Laboratories GmbH, Pasching, Austria), 1% antibiotic/
antimycotic (PAA Laboratories) and 10% foetal calf serum (FCS; PAA Labo-
ratories) at 37°C under 5% CO2. These cells were transfected with the pCI-
neo-DUX4 expression vector to provide a positive control for Western blots
(Figs 5C, 6A, Figs S2A, S3 and S6) or with the empty pCIneo vector as a
negative control (Fig. S3A). For transfections, C2C12 cells (5 9 105) were
seeded in a 75 cm2 flask and transfected 24 hrs later in Opti-MEM
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(Invitrogen, Carlsbad, CA, USA) with 20 lg plasmid and 60 ll Lipofecta-
min2000 (Invitrogen). TE671 cells (1.2 9 106) were seeded in a 75 cm2
flask and transfected 24 hrs later in their culture medium with 10 lg plas-
mid and 32 ll FuGENE6 (Roche Diagnostics, GmbH, Mannheim, Germany).
Cells were harvested 24 hrs post-transfection.
Primary myoblast cultures from control individuals and patients with
FSHD were isolated from muscle biopsies, purified by a selection of
CD56+ cells and established as described [24]. They were grown in colla-
gen-coated dishes (Iwaki Cell Biology, Tokyo, Japan) in DMEM with high
glucose (4.5 g/l), sodium pyruvate and sodium bicarbonate (Sigma-
Aldrich, St Louis, MO, USA) with L-glutamine (4 mM; Sigma-Aldrich),
Gentamycin (50 lg/ml; Sigma-Aldrich), 10% foetal bovine serum (FBS;
Invitrogen) and 1% Ultroser G (Pall BioSepra, Cergy-St-Christophe,
France) at 37°C under 5% CO2. Before experimentation, primary myo-
blasts were seeded in 10 cm or 35 mm collagen-coated dishes, respec-
tively, for Western blot or immunofluorescence, in DMEM with
Gentamycin (50 lg/ml) and 20% FBS. The myogenic differentiation of
confluent cells was induced by decreasing the FBS concentration to 2%.
The proteasome inhibitor MG132 (25 lM or 50 lM; Sigma-Aldrich) was
added to the culture medium 5 hrs before harvesting the cells (Fig. 5).
For transfection, primary myoblasts were seeded in the growth medium
(DMEM/Gentamycin/10% FBS/1% Ultroser G) and transfected 24 hrs
after seeding with Fugene HD (Roche Diagnosis) and plasmid DNA at a
6:2 ratio as described [19]. Myoblasts were then differentiated 5 hrs later
by replacing the medium to DMEM/Gentamicin/2% FBS during 3 days
(Fig. 1). A ‘reverse transfection’ with SiPORTNeoFX transfection agent
(Applied Biosystems, Ambion, Austin, TX, USA) was used to introduce
short interfering (si)RNA against DUX4 or DUX4c (Fig. S2) in primary
myoblasts as described in [19]. Differentiation was induced 5 hrs later
as above and cells were fixed for immunofluorescence after 3 days.
Plasmid constructs
The pCIneo-DUX4 and pCIneo-DUX4c expression plasmids were
described previously in [8, 9, 13] and contain the respective ORF under
control of the CMV promoter. The vector used to determine the trans-
fection efficiency by monitoring of green fluorescence was the pEGFP-
N2 (Clontech, Mountain View, CA, USA).
DUX4 and DUX4c antibodies
The mouse monoclonal antibody against DUX4 (MAb 9A12) was raised
against the 253 last residues of the DUX4 carboxyl-terminal domain as
described in [9]. The anti-PITX1 rabbit serum was raised against a
PITX1-specific peptide as described in [9]. The anti-DUX4c rabbit serum
was raised against a carboxyl-terminal peptide as described in [13]. The
314 rabbit antiserum was raised against a DUX4-specific peptide corre-
sponding to residues 342–356 as described in [17].
Immunodetection by Western blot
The following protocol was specifically developed for the detection of
the endogenous DUX4 protein with MAb 9A12. Whole-cell extracts of
myoblast primary cultures were obtained by lysis in hypertonic buffer
(50 mM Tris pH 7.0, 50 mM NaCl, 0.1% Nonidet P40, 1 mM DTT) and
protease inhibitor cocktail (Sigma-Aldrich) using three freeze/thaw
cycles. Nuclear extracts were prepared with the NE-PER Nuclear and
Cytoplasmic Extraction Reagent kit (Thermo Scientific, Rockford, IL,
USA) according to the manufacturer’s procedure except that nuclei were
lysed with the hypertonic buffer. Forty lg cell lysate or 20 lg nuclear
extract were separated by 10 or 12% PAGE-SDS during 3 to 4 hrs at
100 V and electrotransferred onto a nitrocellulose membrane (GE
Healthcare Europe GmbH, Diegem, Belgium). The electrotransfert was
performed at 4°C in a wet tank with a blotting buffer containing
12.5 mM TRIS, 192 mM Glycine and 20% Methanol, at 160 mA during
90 min. The membrane was stained with Ponceau red to check loading
and migration quality, and a picture was taken for loading control. After
rinsing in PBS, the Western blot was blocked 1 hr at room temperature
in phosphate buffered saline (PBS) with 5% non-fat dry milk, rinsed in
A aa
B b
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Fig. 1 Overexpressed DUX4 is detected in consecutive myonuclei of
individual myotubes. Facioscapulohumeral muscular dystrophy (FSHD)
myoblasts (dFSHD12) were transfected with the pCIneo-DUX4 expres-
sion vector at a low efficiency and differentiation was induced 5 hrs
later. DUX4 (green) was detected by immunofluorescence with the MAb
9A12 monoclonal antibody 3 days after transfection. DUX4 was
detected in myotubes containing either clusters of nuclei (A and B) or
aligned nuclei (C and D). The nuclei were visualized by DAPI staining
(blue). a, b, c and d correspond to enlarged fields from the left boxes.
78 ª 2012 The Authors
Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
PBS and incubated overnight at 4°C with MAb 9A12 (1:1000) in PBS-
BSA 2%. After rinsing in PBS, appropriate secondary antibodies coupled
to HRP (1:5000; GE Healthcare) were added and detected with the
super signal west femto maximum sensitivity substrate (Thermo Scien-
tific) on Amersham Hyperfilm ECL (GE Healthcare).
For immunodetection on muscle biopsy extracts (Fig. 6A and
Fig. S6), the same protocol was used with the homogenization in the
hypertonic buffer. In Figure 6A, 40 lg (F11 and F7) or 80 lg (F10 and
C1) protein extract were loaded. In Figure S6, 40 lg of each protein
extract was loaded. For the 2D gel analysis, an isoelectrofocalization
(IEF) was performed with the IPGphor system (Amersham Pharmacia
Biotech) according to the manufacturer’s instructions, with modifica-
tions as described [29]. Immobiline Dry Strip (pI 3–11), IPG buffer pH
3–11 and electrophoretic reagents were purchased from Amersham
Pharmacia. The second dimension was a PAGE-SDS.
Immunofluorescence
Primary myoblasts seeded on 35 mm collagen-coated dishes (Iwaki Cell
Biology) were fixed 5 min. at room temperature (RT) in 4% paraformal-
dehyde. Cells permeabilization was performed in PBS 0.5% Triton X-
100, 5 min. at RT. After blocking in PBS 20% FBS, cells were incubated
with primary antibodies during 2 hrs at RT. The following antibodies
and dilutions were used: MAb 9A12 (purified: 1/50 or hybridoma culture
medium: 1:1), anti-PITX1 rabbit serum (1/50), anti-DUX4c rabbit serum
(1/50), rabbit polyclonal antidesmin ab15200 (1/200; Abcam, Cam-
bridge, UK), rabbit MAb anticleaved PARP (1/200, overnight at 4°C; Cell
Signaling, Danvers, MA, USA). After washing and blocking, cells were
incubated during 1 hr at RT with Alexa Fluor secondary antibodies goat
antimouse 488 and antirabbit 555 (1/100; Invitrogen). After washing,
cells were covered by 5 ll of Vectashield mounting medium (Vector
Laboratories, Burlingame, CA, USA) containing 4,6-diamidino-2-pheny-
lindole (DAPI) and by a coverslip.
The detection of DNA fragmentation in DUX4-positive nuclei was per-
formed with the Apoptag Red In Situ Apoptosis Detection kit (Millipore,
Billerica, MA, USA), according to the manufacturer’s instructions.
Microscopy
Microscopy images were collected with the following workstations: the
Montpellier RIO Imaging facility at the CRBM, Montpellier, France (http://
www.mri.cnrs.fr); the imagery platform at the IBMM, ULB, Belgium
(http://www.cmmi.be) and a Nikon Microscope Eclipse 80i with a DS-U3
DS Camera control Unit and the NIS element-BR analysis software. Plan
Fluor 20 X, Plan Fluor 409 and 609 Apo-VC high-resolution oil immer-
sion objectives were used with 350-, 480- and 540- nm excitation for the
4,6-diamidino-2-phenylindole (DAPI), fluorescein isothiocyanate (FITC)
and tetramethylrhodamine isothiocyanate (TRITC) channel respectively.
Quantifications and Statistics
The number of DUX4-positive nuclei (Fig. 2B and Fig. S2C) was
counted from at least 10 random fields (209 objective). The percentage
was calculated relatively to the number of DAPI-positive nuclei per field
and the histograms represent the percentage mean. The DUX4 intensity
mean per field (Fig. 2C) was measured using the NIS element-BR analy-
sis software. Intensity values below the threshold (Th: corresponding to
DUX4 intensity mean in disorganized culture) are considered as null.
The significance was evaluated by an ANOVA test and a multiple compari-
son of means (Tukey Contrasts) using the ‘R Foundation for Statistical
Computing 2.14.0’. An arcsine transformation (p′ = arcsin√p where
p = proportion), commonly used for proportions, was applied beforehand
to the data. **P < 0.01 was considered significant.
Results
Exogenous DUX4 proteins are detected in
consecutive nuclei of individual myotubes
In a first experiment, we wanted to optimize immunostaining condi-
tions that would allow DUX4 detection in very few myonuclei. We
used an FSHD primary myoblast line (dFSHD12) that forms mostly
disorganized myotubes but also some atrophic ones [24]. We trans-
fected these cells at the myoblast stage with a DUX4 or EGFP
expression vector at a very low efficiency and induced fusion into
myotubes 5 hrs later. The immunofluorescence was performed
3 days later with MAb 9A12, a monoclonal antibody we had previ-
ously developed against the DUX4 carboxy-terminal region [9].
As expected, only 12% and 16% of the transfected cells
expressed high levels of EGFP or DUX4 respectively (data not shown).
About 58% of EGFP-expressing nuclei were present in myoblasts and
42% in myotubes. Surprisingly, the majority (88%) of the DUX4-posi-
tive nuclei were found in pluri-nucleated cells (myotubes) and only
12% in cells containing a single nucleus (myoblasts). The DUX4 im-
munostaining followed an intensity gradient in consecutive nuclei of a
given myotube (Fig. 1). DUX4 was detected either in disorganized
myotubes containing myonuclei clusters (>10 nuclei) (Fig. 1A and B)
or in atrophic myotubes with a small number of aligned nuclei (from
two to eight nuclei) (Fig. 1C and D). A similar staining pattern was
observed using a rabbit serum directed against a DUX4-specific pep-
tide (data not shown, Ab #314; [17]). In these experiments, when
DUX4 was found in at least one myotube nucleus, the consecutive
myonuclei were often also DUX4 positive. These intensity gradients
suggested that the DUX4 mRNA transcribed in one myonucleus was
translated in the adjacent cytoplasm domain into proteins that could
be imported in several neighbouring nuclei, a diffusion mechanism
previously described for other muscle proteins [25–28, 30].
The endogenous DUX4 protein is expressed in
differentiating FSHD myoblasts
We have previously immunodetected the DUX4 protein with MAb
9A12 in primary cell cultures derived from FSHD muscles but not
from healthy controls [9]. We have now further demonstrated this
antibody specificity (see Figure S1, and RNA interference experiment
Figure S2) and used it to detect DUX4 on Western blots prepared with
three additional FSHD and two control primary myoblast lines. DUX4
was detected not only in extracts of confluent myoblasts confirming
our previous data [24] but also in differentiated myotubes (Fig. S3).
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Intriguingly, we detected a very weak signal in one control sample
(CTL3 diff) prepared from cells grown 6 days in the differentiation
medium (Fig. S3A).
DUX4 was detected in differentiated FSHD primary myoblast cul-
tures whether they presented a higher proportion of either disorga-
nized or atrophic myotubes (Fig. 2, Table 1). The DUX4-positive nuclei
were counted in triplicate in 10 random fields and found significantly
higher in the atrophic and disorganized FSHD myotube cultures than in
the controls (Fig. 2B, **P < 0.01). The number of nuclei with a strong
DUX4 immunofluorescence was the highest in the atrophic FSHD cul-
tures (**P < 0.01). The average of DUX4 nuclear staining intensity
was about threefold lower and similar in control and disorganized
FSHD cultures, except for a single atrophic myotube found in the latter
(Fig. 2C). The DUX4 expression level differed in individual FSHD pri-
mary myoblast lines with no correlation with the non-affected or
affected (*) status of the muscle it had been derived from (Figs S1, S3
and Table 1). All the data concerning the FSHD and control primary
myoblast lines used in this study (muscle type, myotube phenotype,
etc.) are summarized in Table 1 and Table S1 respectively.
The endogenous DUX4 protein is expressed in
myoblasts and in consecutive myotube nuclei
A co-immunostaining was performed with MAb 9A12 and a rabbit
serum directed against desmin to determine whether DUX4-positive
Fig. 2 Endogenous DUX4 expression in facioscapulohumeral muscular dystrophy (FSHD) and control primary myotubes. (A) DUX4 (green) was
detected by immunofluorescence with MAb 9A12 in the nuclei of disorganized (dFSHD12) and atrophic (aFSHD3) FSHD or control (CTL12) myo-
blasts 4 days after the induction of differentiation. DAPI (blue) was used to visualize nuclei. (B) Quantification of DUX4-positive nuclei in aFSHD3
and dFSHD12 myotubes compared with control (CTL12) myotubes 4 days after the induction of differentiation. The number of DUX4-positive nuclei
was counted in 30 random fields of three independent experiments (10 fields per experiment). Two representative fields (1, 2) used for the quantifi-
cation are shown in (A) for each cell line. The percentage was calculated relatively to the number of DAPI-positive nuclei, and the histogram repre-
sents the percentage means. The significance was evaluated by an ANOVA test. **P < 0.01 was considered significant. (C) Quantification of DUX4-
positive nuclei intensity in aFSHD3 and dFSHD12 myotubes compared with control (CTL12) myotubes 4 days after the induction of differentiation.
The intensity of DUX4-positive nuclei was measured in 30 random fields of three independent experiments. Intensity values below the threshold
(Th) are considered as null. Each value was plotted. Rectangles represent the intensity means. The significance was evaluated by an ANOVA test.
**P < 0.01 was considered significant.
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nuclei belonged to either isolated myoblasts or myotubes. A total of
5% of the nuclei stained for DUX4 among which 16% were in
non-fused myoblasts found in the vicinity of myotubes. Among these
DUX4-positive myoblasts, 77% presented the staining as nuclear foci
(Fig. 3A and B). Again, when DUX4 was detected in at least one
myotube nucleus, it also was in the adjacent myonuclei. In myotubes,
the DUX4 staining appeared either in clusters of nuclei with various
intensities (Fig. 3C) or in aligned nuclei with a clear intensity gradient
(Fig. 3D). Some DUX4-positive nuclei presented an abnormal mor-
phology that might reflect its toxicity. However, no overt apoptosis
markers could be detected in these nuclei (Fig. S4).
DUX4 and PITX1 are either coexpressed or
expressed in distinct nuclei of FSHD myotubes
We have previously shown that DUX4 overexpression induced the
endogenous Pitx1 gene in mouse C2C12 cells and that the induced
Pitx1 nuclear protein colocalized with DUX4 [9]. In the present study,
we detected the endogenous DUX4 and PITX1 proteins in human
FSHD primary myotubes by a co-immunofluorescence using MAb
9A12 and a rabbit serum against PITX1 [9] (Fig. 4). About 4% of the
nuclei were positive for DUX4 in both atrophic (Fig. 4B and E) and
disorganized FSHD myotubes (Fig. 4A, C and D). PITX1 staining was
found in 5% of the nuclei either in the DUX4-positive nuclei with
partial colocalization (1%) (Fig. 4A, merge pictures) or in different
nuclei (4%) (Fig. 4B–E, merge pictures and arrows). Like DUX4,
PITX1 was often detected in consecutive myonuclei (Fig. 4A, C–E). In
a given myotube, the PITX1-positive nuclei were often localized close
to a DUX4-positive nucleus (Fig. 4D and E).
The DUX4 and PITX1 protein half-lifes are
regulated by the proteasome
The staining patterns we observed above for DUX4 and the product of
its PITX1 target gene suggested a dynamic expression regulated by
proteolysis. As previously mentioned [9] and according to the PEST-
find software (http://emboss.bioinformatics.nl/cgi-bin/emboss/epest-
find), the PITX1 protein harbours a PEST motif (Fig. S5A), i.e. a
sequence enriched in proline (P), glutamic acid (E), serine (S) and
threonine (T) that targets proteins for rapid degradation by the pro-
teasome [31]. Although PITX1 was immunodetected in standard con-
ditions (Figs. 4 and 5Aa’), we could improve its labelling by addition
of MG132 to the culture medium for 5 hrs prior to cell harvest. In the
presence of this proteasome inhibitor, PITX1 presented a different in-
tranuclear staining pattern (Fig. 5Ab’ and B, enlarged inset). Interest-
ingly, as was observed for DUX4, some nuclei presented a strong
Table 1 Summary of data about DUX4 expression in FSHD primary myoblasts. Name of the FSHD cell line (NB: ‘line’ refers to the myoblast
population derived from a single biopsy); age and gender of the patient (M: male; F: female); number of D4Z4 units; site of the muscle
biopsy (T: trapezius; Q: quadriceps (vastus lateralis); FB: femoral biceps); score on the Brooke–Vignos scale defining the clinical status of
upper and lower limb muscles, respectively, where high values define affected muscles and low values define non-affected muscles [44, 45];
predominant phenotype of the derived myotubes and MFI (myoblasts fusion index: ratio between the nuclei present in myotubes versus the
total number of nuclei in a given microscope field; the proportion of atrophied myotubes in a culture is inversely correlated with the MFI).
DUX4 protein detection is indicated (+) as well as the number of days in differentiation medium (diff) and the method used (WB:
immunodetection on Western blot; IF: immunofluorescence). The information about the patients and the morphological characteristics of each
FSHD cell line was previously determined in [24].
Code# Age Gender
D4Z4
units
Muscle
type
(Brooke-
Vignos
scale)
Myotubes
phenotype (MFI)
DUX4 expression
(Methods)
Differentiation state (Figures)
aFSHD1* 30 M 5 T(4-5) Atrophic (18%) ++(IF, WB) -WB: aligned myoblasts (Fig. S3A)-IF:
diff 4 (Figs 4B, 5B, S1A)
aFSHD3 32 F 7 Q(1-1) Atrophic (37%) +(IF,WB) -WB: diff 3 (Fig. S2A); diff 4
(Fig. 5C)-IF: diff 4 (Figs 2A, 4E, S4A)
aFSHD5 53 M 6 Q(2-3) Atrophic (42%) +(WB) Diff 4 and diff 8 (Fig. S3B)
a/dFSHD7 53 M 9 FB(2-2) Atrophic (49%) +(WB) Aligned myoblasts (Fig. S3A)
dFSHD12 38 F 7 Q(1-1) Disorganized (60%) +(IF, WB) -WB: diff 4 (Fig. S3B)-IF: diff 4
(Figs 1, 2A, 4C/D, 5B, S1B, S4A-C);
diff 5 (Fig. 3)
dFSHD13* 42 F 8 Q(4-4) Disorganized (70%) +(IF) -IF: diff 4 (Figs 4A, 5A, S1B)
#All these samples were characterized in Barro et al., 2010.
*myoblasts derived from affected muscle.
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PITX1 labelling that progressively decreased in the consecutive nuclei
(Fig. 5Ab’). These data suggested a gradual diffusion within a given
myotube of both DUX4 and PITX1 proteins in nuclei adjacent to an
initial single nucleus where their gene had been activated. As men-
tioned above, we observed either partial DUX4/PITX1 colocalization or
mutually exclusive labelling (Fig. 5B, arrows and dotted arrows).
DUX4 detection was improved by MG132 addition even though it
only displayed poorly predicted PEST motifs in its carboxyl-terminal
domain. However, the PEST score (a combination of enrichment in D,
E, P, S and T residues and hydrophobicity) of some DUX4 residues
was just below the threshold score (5.0) (Fig. S5B). In addition,
according to the Protparam software (http://www.expasy.ch/tools/
protparam.html), the DUX4 protein is considered unstable with an
instability index of 71.36.
To confirm a DUX4 stabilization by the proteasome inhibition, we
prepared a Western blot with nuclear extracts of proliferating primary
myoblasts or myotubes either treated with MG132 or not, and we im-
munodetected DUX4 with MAb 9A12 (Fig. 5C). Regardless of MG132
treatment, a much stronger 52-kD band was detected in differentiated
as compared with proliferating myoblasts. The cultures treated with
the proteasome inhibitor presented a stronger DUX4 signal intensity in
this experiment. In addition, lower molecular weight bands detected
with MAb 9A12 on this Western blot had a decreased intensity upon
MG132 treatment, thus showing they resulted from proteolysis
(Fig. 5C: red braces).
The DUX4 protein is expressed in FSHD muscle
biopsies
To this date, no report of DUX4 protein detection in FSHD muscle
biopsies has been published ([11], reviewed in [20]). This is indeed a
technical challenge as the DUX4 protein is unstable and likely
expressed in pulses in very few nuclei. For this experiment we
used needle biopsies from different muscles (deltoid, trapezius,
quadriceps) of two patients with FSHD and a matching control. We
prepared Western blots with biopsy protein extracts and could immu-
nodetect the 52-kD band with MAb 9A12 in the FSHD samples but not
in the control (Fig. 6A). As expected, DUX4 was observed in total and
nuclear but not cytoplasmic extracts. A lower molecular weight band,
which most likely corresponded to a DUX4 proteolysis product, was
observed and was stronger in the nuclear extracts than in the total
extracts probably because of a longer experimental procedure
(Fig. 6A). In addition, we characterized the immunodetected protein by
2-D gel electrophoresis (isoelectrofocusing and polyacrylamide-SDS
gel) followed by a transfer to a Western blot and immunodetection
A
B
C
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c
b
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E
Fig. 3 DUX4 is expressed in facioscapu-
lohumeral muscular dystrophy (FSHD)
myoblasts and in consecutive nuclei in
FSHD myotubes. Co-immunofluorescence
with MAb 9A12 (green) and a rabbit
serum directed against desmin (red) on
FSHD (dFSHD12) and control (CTL10) pri-
mary myotubes, 5 days after the induction
of differentiation. a, b and c correspond to
enlarged fields from the left boxes. Arrows
indicate the most stained nuclei and the
dotted arrows the intensity gradient of the
DUX4 staining (D: merge panel). DAPI
(blue) was used to visualize nuclei.
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with MAb 9A12. Owing to the limited material obtained from each
biopsy, we used a sample obtained from another patient with FSHD.
A single spot was observed at the expected isoelectric point (8.6) and
molecular weight (52 kD) of DUX4 (F6 in Fig. 6B) as previously
reported for an FSHD myoblast culture [32]. Intriguingly, in the same
experimental conditions we could not detect DUX4 in an affected
FSHD muscle (F15* in Fig. 6B). As described in the supporting infor-
mation, DUX4 was detected in two additional FSHD muscle biopsies
but not in one control, and in some FSHD surplus obtained from
scapular fixation (Figs S6A and B). The characteristics of all the FSHD
muscle biopsies tested in this study are shown in Table S2.
Discussion
DUX4 is induced during myoblast differentiation
Several groups besides ours have now demonstrated the presence of
polyadenylated DUX4-fl mRNA in FSHD muscle cells [9–12]. Although
we could previously demonstrate DUX4 protein expression in proliferat-
ing FSHD but not control myoblasts [9], DUX4 detection is very diffi-
cult. Indeed, Snider et al. determined that DUX4 was expressed at a
relatively abundant amount in only about 1/1000 primary myoblasts
[11]. In the present study we confirm a similar low expression for the
DUX4 protein by Western blot analysis of proliferating FSHD primary
myoblasts. However, in myoblasts grown 4 days in a differentiation
medium we detected an increase in DUX4 protein by Western blot anal-
ysis (Fig. 5C), which correlated with a higher number of DUX4-positive
nuclei (1/200; Fig. 2A and B). Both the DUX4 mRNA ([9, 12]; reviewed
in [20]) and protein (the present study) are easier to detect in myotu-
bes than in proliferating myoblasts, suggesting that DUX4 transcription
is induced upon differentiation resulting in both increased expression
levels and a larger number of expressing nuclei. DUX4 was detected in
cultures derived from both affected and non-affected FSHD muscles,
either in non-fused myoblasts or in adjacent nuclei of some myotubes.
The number of DUX4-positive nuclei was similar in cultures of both
mostly atrophic or disorganized phenotypes, but the staining inten-
sity was stronger in the atrophic type, in keeping with the recently
A
B
C
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F
Fig. 4 DUX4 and PITX1 detections in fa-
cioscapulohumeral muscular dystrophy
(FSHD) myotubes. DUX4 (green) and
PITX1 (red) were detected by immunoflu-
orescence with MAb 9A12 or the rabbit
anti-PITX1 serum in nuclei of primary
myotubes 4 days after the induction of
differentiation. Colocalization of DUX4 and
PITX1 staining appears yellow (Merge).
DAPI (blue) was used to visualize nuclei.
dFSHD13 and aFSHD1 are derived from
an affected muscle (*) and dFSHD12 and
aFSHD3 from a non-affected muscle.
Arrows indicate positive nuclei for DUX4
or PITX1 staining, and dotted arrows indi-
cate PITX1 or DUX4-negative nuclei.
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demonstrated role of DUX4 in the atrophic process [19]. Interestingly,
we have also detected a weak DUX4 signal in control primary myo-
blasts, but only upon differentiation. The number of DUX4-positive
nuclei was significantly lower than in FSHD myotubes, but we cannot
exclude that DUX4 might be expressed normally, in a very limited win-
dow, during the myoblast differentiation process.
The DUX4 expression pattern in FSHD myotubes
In this study, FSHD myotubes presented a DUX4 staining pattern
often characterized by one brightly stained nucleus and a progres-
sive decrease in the signal intensity in consecutive nuclei. Similar
pictures were independently observed by immunocytochemistry
A
B
C
a ba′ b′
Fig. 5 DUX4 and PITX1 stabilization in facioscapulohumeral muscular dystrophy (FSHD) myotubes treated with MG132. (A) PITX1 (red) was
detected by immunofluorescence with the rabbit anti-PITX1 serum in nuclei of myotubes 4 days after the induction of differentiation (a’, b’). Phase
contrast microscopy was used to visualize the myotube morphology and position of the nuclei (a, b). b and b’ correspond to primary myotubes
treated with 25 lM MG132, a proteasome inhibitor, for the last 5 hrs in culture before fixation. Arrows indicate the most stained nuclei and the dot-
ted arrows the intensity gradient of PITX1 staining. (B) DUX4 (green) and PITX1 (red) were detected by immunofluorescence with MAb 9A12 or the
rabbit anti-PITX1 serum, respectively, in nuclei of FSHD (aFSHD1 and dFSHD12) primary myotubes 4 days after the induction of differentiation. The
myotubes were treated with 25 lM MG132 as in (A). Colocalization of DUX4 and PITX1 staining appears yellow (Merge). DAPI (blue) was used to
localize nuclei. Arrows indicate positive nuclei for DUX4 and PITX1 staining and dotted arrows indicate negative nuclei for DUX4 and PITX1 staining.
(C) Nuclear proteins extracted from aFSHD3 primary myoblast were analysed by 12% PAGE-SDS followed by Western blotting and immunodetection
with MAb 9A12 as described in Materials and Methods. Myotubes were treated with 0 or 25 lM MG132 as indicated 5 hrs before harvest. Nuclear
extracts were prepared using the NE-PER kit at the proliferation state (pro) or 4 days after the induction of differentiation (diff 4). Total extracts of
TE671 cells transfected with pCIneo-DUX4 were used as a positive control (C+). DUX4 proteolysis products observed in the absence of MG132 are
shown by red braces. Ponceau red staining of the membrane was used as loading control.
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with another antibody, in a very recent publication [33]. This pat-
tern suggests that DUX4 could diffuse to several nuclei in a given
myotube and is typical of the limited diffusibility of nuclear pro-
teins in muscle fibres ([25, 27] see Introduction). Indeed, in these
multinucleated cells, an individual nucleus could independently
express DUX4 mRNAs that would be exported and translated in
the adjacent cytoplasmic domain. The DUX4 protein could then dif-
fuse in the common cytoplasm, and owing to its NLS, it could be
imported into several myonuclei in the vicinity of the one that ini-
tially transcribed the gene (Fig. 7: Panel I). Such an expression
pattern is well known for other muscle nuclear proteins (see Intro-
duction) but is described here for the first time in a pathological
context. The initial stochastic DUX4 gene activation in an iso-
lated nucleus could occur by chromatin remodelling according to
different models [34–37]. The DUX4 transcription factor targets a
large gene set, leading to increased sensitivity to oxidative stress
and myogenic differentiation defects [18]. Some of these genes
encode other transcription factors among which we identified the
Pitx1 gene as a direct DUX4 target [9]. This was confirmed by
activation of a luciferase reporter gene fused to the human PITX1
promoter (S. Charron, unpublished data) and more recently by
coupled transcriptomic and chromatin immunoprecipitation studies
of DUX4-activated genes in human myoblasts [21]. We have
observed in the present study that the PITX1 and DUX4 protein
expression patterns are similar which is in keeping with their diffu-
sion in consecutive myonuclei. Our data suggest a dynamic model
of how the inappropriate DUX4 expression in a limited number of
FSHD myonuclei could lead to DUX4 protein diffusion to several
nuclei in which it could activate several target genes such as
PITX1 (Fig. 7: Panel II). The transcriptional cascade initiated by
DUX4 could be further extended because PITX1 is itself a tran-
scription factor that could similarly diffuse to additional nuclei and
target additional genes. In several recent publications TP53 [19,
23, 38] as well as the E3 ubiquitin ligases Atrogin-1 and MURF1
[19, 22] which are associated with muscle atrophy were described
as parts of the deregulation cascade induced by DUX4. The initial
DUX4 trigger in a single nucleus would thus be amplified through
a transcriptional cascade that would extend to the whole myotube
or myofiber and globally lead to muscle atrophy and inflammation,
which are key features of FSHD. This concept is in agreement with
a variant of the ‘majority rules’ model recently proposed by Ehrlich
and Lacey which involved ‘oscillating non-toxic generation of
DUX4-fl transcript throughout the FSHD myotube population’ [39].
The DUX4 and PITX1 proteins half-lifes are
regulated by the ubiquitin-proteasome pathway
Our data indicate that, similar to other transcription factors, the DUX4
protein stability appears highly regulated, likely in relation to a role in
early development [11]. We found that DUX4 was degraded by the
ubiquitin-proteasome pathway (UPP), likely targeting its carboxyl-ter-
minal domain, which contains sequences with destabilization proba-
bility (Fig. S5B). Because it is a very potent transcriptional activator
[40], very small amounts of DUX4 could be sufficient to initiate the
deregulation cascade. We should also mention that although the pro-
teasome usually completely degrades its substrates into small pep-
tides, in a few cases, its proteolytic activity yields biologically active
protein fragments as described for several transcription factors (NF-
kappa B, Spt23p and Mga2p) [41]. In future studies, it will be interest-
ing to evaluate whether such a proteasomal processing could also
occur for members of the FSHD transcriptional cascade, leading to
smaller fragments that might exert some biological activity. Finally,
our results suggested that other degradation pathways could interfere
with DUX4 stability. Indeed, the use of MG132 alone did not always
sufficiently stabilize DUX4 to allow its codetection with the product of
its PITX1 target gene. The dynamic expression model presented here,
together with an asynchronous regulation of their half-life by the pro-
teasome could explain why the DUX4 and PITX1 proteins were
Fig. 6 DUX4 expression in facioscapulohumeral muscular dystrophy
(FSHD) muscle biopsies. (A) Nuclear (Nuc), cytoplasmic (Cyt) or total
(Tot) protein extracts from FSHD (F11, F7, F10) or control (C1) muscle
biopsies were analysed by 12% PAGE-SDS followed by Western blotting
and immunodetection with MAb 9A12. The positive control (C+) is an
extract of C2C12 cells transfected with pCIneo-DUX4. Ponceau red
staining of the membrane was used for loading control. (B) Total
extract of the F6 and F15 muscle biopsies was analysed by 2D electro-
phoresis (IEF-PAGE-SDS, see Materials and Methods), followed by
Western blotting and an immunodetection with MAb 9A12. The charac-
teristics of these samples are reported in Table S2. (*) FSHD biopsies
derived from an affected muscle.
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Fig. 7 Dynamic model of propagation and initiation of a transcriptional cascade. I: Activation and diffusion. A myotube is a multinucleated cell with a
common cytoplasm in which individual nuclei can independently activate gene expression. In an facioscapulohumeral muscular dystrophy (FSHD)
myotube, the DUX4 gene is activated in one given nucleus ➀. The DUX4 gene is then transcribed into an mRNA that terminates at the polyadenyla-
tion site located in the pLAM region. The mRNA is translocated into the cytoplasm domain close to the activated nucleus and it is translated, yield-
ing several molecules of DUX4 protein ➁. The DUX4 protein that carries a nuclear localization signal (NLS) could diffuse in the cytoplasm, and be
transported into several neighbouring nuclei ➂. II: Cascade initiation and amplification. In each nucleus that has imported the DUX4 protein, this
transcription factor directly activates a number of genes as shown here for the PITX1 gene ➊. The PITX1 gene is thus transcribed, its mRNA is
translocated into the cytoplasm domain close to the activated nuclei and translated ➋. The molecules of PITX1 protein can diffuse in the cytoplasm
and, because they also carry a NLS, they will be imported into more neighbouring nuclei ➌.The transcriptional cascade initiated by DUX4 can further
extend because PITX1 is also a transcription factor and targets additional genes such as TP53. At each step of this transcription cascade, the num-
ber of activated nuclei and expressed genes increases, causing an amplification of the initial trigger, i.e. DUX4 gene activation in a single nucleus.
Globally, the DUX4 transcription cascade leads to muscle atrophy, inflammation, oxidative stress and decreased differentiation potential, the key fea-
tures of FSHD.
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detected either individually in separate nuclei or together in identical
nuclei. In the present study, the PITX1 protein was easier to detect in
FSHD myotubes than in FSHD muscle biopsies although biopsies had
been used to demonstrate its FSHD-specific induction at the mRNA
level [9]. We suspect that PITX1 expression is variable, depending on
its expression kinetics during myogenic differentiation, the myotube
phenotype, the degree of muscle damage and its proteolysis rate.
The DUX4 protein presents variable subnuclear
localization
Our studies indicated different intranuclear distribution patterns for
DUX4, i.e. punctated or in larger foci. Intriguingly, we have not
observed a ring staining as previously described in cells with forced
DUX4 expression [17]. The nature and the roles of these nuclear foci
still remain to be determined. Like many transcription factors, chro-
matin proteins, and RNA-processing factors, DUX4 might be com-
partmentalized and accumulate in distinct nuclear domains that are
involved in specific processes (reviewed by [42]). Although the mor-
phology of most nuclei with DUX4-positive foci appeared quite nor-
mal, we have observed larger nuclei, some with an irregular outline,
and a few fragmented nuclei characteristic of apoptosis (Fig. S4A).
However, nuclei expressing the endogenous DUX4 protein in FSHD
myoblasts did not exhibit cleaved-PARP staining (Fig. S4B) nor DNA
fragmentation (Fig. S4C). Nuclei with the opposite staining pattern
(cPARP+/DUX4) were increased in FSHD myoblasts and might
reflect an apoptotic process initiated by a pulse of DUX4 expression,
followed by DUX4 protein degradation, similarly to the explanation we
proposed above to explain the presence of PITX1+/DUX4 nuclei.
Another point to consider is that although DUX4 overexpression
induced caspase 3/7 activity and cell death [17, 18], its toxicity was
dose dependent. Indeed, a moderate DUX4 expression in C2C12 cells
only reduced myogenic differentiation and increased sensitivity to oxi-
dative stress without causing cell death [18]. Further experiments
should define whether the presence or shape of DUX4 nuclear foci
could be related to the cell cycle or to cellular damage. As described
for other transcription factors, nuclear foci could also correspond to
sites of target gene transcription or storage [43].
DUX4 expression in FSHD muscle
Although the DUX4-fl mRNA was described by several studies in
muscle samples, the DUX4 protein has only been detected in testes,
where it is strongly expressed [11]. In the present study, we could for
the first time detect the DUX4 protein in FSHD muscle biopsies, par-
ticularly in non-affected muscles. In affected muscles, the signal was
often at the limit of detection and even missing in a biopsy of a
severely affected muscle that presented a major loss of muscle fibres
and important fibrosis, suggesting that DUX4 expression is an early
event in FSHD.
In conclusion, DUX4 was induced upon differentiation and
detected in about 1/200 myonuclei in a panel of FSHD myotubes. Its
expression pattern suggested the DUX4 gene transcription occurred
in pulses in rare nuclei followed by a diffusion of the expressed
protein to additional nuclei, a mechanism previously described for
muscle nuclear proteins in non-pathological contexts. We propose
that the DUX4 transcription factor further activates a deregulation
cascade in every nucleus to which it has diffused. The transcription
factors expressed from some of its target genes such as PITX1 will
similarly diffuse to additional nuclei thus further extending the dereg-
ulation cascade leading to fibre atrophy or death.
Consistent with a causal role of DUX4 in FSHD, DUX4 is
expressed in FSHD muscle, except in a very affected context. Our
study opens new perspectives about DUX4 involvement in FSHD, i.e.
how such a rare protein could cause damages leading to a myopathy.
This model should be strengthened in the future by understanding the
trigger to DUX4 transcription pulses, monitoring the DUX4 protein
diffusion and deepening our knowledge of the resulting gene deregu-
lation cascade.
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